All Translocation Panel (Oncquest Lab)

Function

The All Translocation Panel is a sophisticated molecular genetic test designed to detect chromosomal rearrangements (translocations) associated with Acute Lymphoblastic Leukemia (ALL). Translocations occur when a piece of one chromosome breaks off and attaches to another chromosome, often creating 'fusion genes' that drive the uncontrolled growth of white blood cells.

Why it is Ordered

This panel is critical for the diagnosis, classification, and risk-stratification of ALL. Identifying specific translocations helps oncologists determine the aggressiveness of the cancer and select targeted therapies. It is also used to monitor 'Minimal Residual Disease' (MRD) following chemotherapy or bone marrow transplantation.

Associated Conditions

• Philadelphia Chromosome (t(9;22)): This involves the BCR-ABL1 fusion and is a hallmark of certain high-risk leukemias, requiring specific TKI inhibitors.
• t(12;21): Associated with the ETV6-RUNX1 fusion, generally indicating a more favorable prognosis in pediatric ALL.
• t(4;11): Involves the KMT2A (MLL) gene, often seen in infant leukemias and associated with a more aggressive course.

Impact on Treatment

Modern oncology relies on these genetic markers to move away from 'one-size-fits-all' chemotherapy toward precision medicine. The presence or absence of these translocations can fundamentally change the duration and intensity of the treatment protocol.